Pupillary Light Reflexes are Associated with Autonomic Dysfunction in Bolivian Diabetics But Not Chagas Disease Patients by Halperin, Anthony et al.
Am. J. Trop. Med. Hyg., 94(6), 2016, pp. 1290–1298
doi:10.4269/ajtmh.14-0775
Copyright © 2016 by The American Society of Tropical Medicine and Hygiene
Pupillary Light Reflexes are Associated with Autonomic Dysfunction in Bolivian
Diabetics but not Chagas Disease Patients
Anthony Halperin,†‡ Monica Pajuelo,† Jeffrey A. Tornheim,* Nancy Vu, Andrés M. Carnero, Gerson Galdos-Cardenas,
Lisbeth Ferrufino, Marilyn Camacho, Juan Justiniano, Rony Colanzi, Natalie M. Bowman, Tiffany Morris, Hamish MacDougall,
Caryn Bern, Steven T. Moore, Robert H. Gilman, and the Chagas Working Group in Bolivia and Peru
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Laboratory of Infectious Diseases Research, Universidad
Peruana Cayetano Heredia, Lima, Peru; Combined Internal Medicine and Pediatrics Residency Program, Yale School of Medicine, New Haven,
Connecticut; University of Utah, Salt Lake City, Utah; Universidad Católica Boliviana “San Pablo,” Santa Cruz de la Sierra, Bolivia;
Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland; Hospital Universitario Japonés, Santa Cruz de la Sierra,
Bolivia; Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina; Department of Neurology,
Icahn School of Medicine at Mount Sinai, New York City, New York; School of Psychology, University of Sydney, Sydney, Australia;
Division of Epidemiology and Biostatistics, University of California San Francisco School of Medicine, San Francisco, California
Abstract. Autonomic dysfunction is common in Chagas disease and diabetes. Patients with either condition compli-
cated by cardiac autonomic dysfunction face increased mortality, but no clinical predictors of autonomic dysfunction
exist. Pupillary light reflexes (PLRs) may identify such patients early, allowing for intensified treatment. To evaluate the
significance of PLRs, adults were recruited from the outpatient endocrine, cardiology, and surgical clinics at a Bolivian
teaching hospital. After testing for Chagas disease and diabetes, participants completed conventional autonomic testing
(CAT) evaluating their cardiovascular responses to Valsalva, deep breathing, and orthostatic changes. PLRs were mea-
sured using specially designed goggles, then CAT and PLRs were compared as measures of autonomic dysfunction.
This study analyzed 163 adults, including 96 with Chagas disease, 35 patients with diabetes, and 32 controls. PLRs were
not significantly different between Chagas disease patients and controls. Patients with diabetes had longer latency to
onset of pupil constriction, slower maximum constriction velocities, and smaller orthostatic ratios than nonpatients with
diabetes. PLRs correlated poorly with CAT results. A PLR-based clinical risk score demonstrated a 2.27-fold increased
likelihood of diabetes complicated by autonomic dysfunction compared with the combination of blood tests, CAT, and
PLRs (sensitivity 87.9%, specificity 61.3%). PLRs represent a promising tool for evaluating subclinical neuropathy in
patients with diabetes without symptomatic autonomic dysfunction. Pupillometry does not have a role in the evaluation
of Chagas disease patients.
INTRODUCTION
Cardiac autonomic dysfunction is a progressive disorder
observed in several chronic diseases including Chagas dis-
ease and diabetes. In both Chagas disease and diabetes,
patients with autonomic dysfunction face higher mortality,
either from arrhythmias in Chagas disease or myocardial
infarctions in diabetes.1,2 Several conventional autonomic
testing (CAT) protocols exist to evaluate cardiovascular
responses to provocative tests like the Valsalva maneuver,
orthostatic change, and deep breathing.1,3–6 Though autonomic
dysfunction is not the direct cause of death, CAT can identify
Chagas disease patients with abnormal cardiac conduction
and can identify subclinical autonomic dysfunction before
symptom onset.7,8 Diabetic patients also develop subclini-
cal autonomic dysfunction affecting multiple organ systems,
which can precede overt peripheral neuropathy, cardiac arrhyth-
mias, and myocardial infarctions.9 CAT is unfortunately lim-
ited by the fact that many patients cannot participate in these
tests, either due to compromised extremities or functional
status from diabetes or due to heart failure in Chagas disease.
Furthermore, diabetic autonomic dysfunction identified by
CAT is frequently too advanced for changes in medical man-
agement to impact associated mortality rates.10
Evaluation of pupillary light reflexes (PLRs) may allow
earlier evaluation of autonomic function in these patients by
observing changes in different nervous pathways. Sympathetic
innervation relaxes the ciliary body of the iris causing pupil-
lary dilation, which affects baseline pupil radius and velocity
of redilation after light exposure. Similarly, parasympathetic
innervation causes contraction of the circular muscle of the
iris, which affects amplitude of pupillary reaction and maxi-
mum constriction velocity after light exposure (Figure 1).11–13
PLR abnormalities precede CAT abnormalities and symp-
tomatic neuropathy in diabetes but have not been evaluated
in Chagas disease.11,14,15 If PLRs could differentiate people
with these diseases, they would be useful screening tools to
identify patients who would benefit from intensified treat-
ment. To evaluate PLR variation between healthy controls,
Chagas disease patients, and patients with diabetes, we
conducted a cross-sectional study of autonomic function by
PLR and CAT among urban outpatients at a hospital with
high rates of both diseases.
MATERIALS AND METHODS
Ethical approval. This study was approved by the institu-
tional review boards of Johns Hopkins University, Asociación
Benéfica PRISMA, and the Hospital Universitario Japonés.
Informed consent was obtained from all participants prior
to participation. After providing informed written consent,
patients were included based upon known disease status.
Site and participants. This study was conducted at Hospital
Universitario Japonés, a public hospital in Santa Cruz, Bolivia,
serving ∼60% of the city’s 1.1 million people. Vector-borne
transmission of the parasite responsible for Chagas disease
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does not occur within urban Santa Cruz, though migration
from endemic areas is common.
Participants with Chagas disease and diabetes were recruited
from the combined waiting room of the hospital’s adult out-
patient specialty clinics, where cardiology, endocrinology, and
surgery patients register. Control patients without diabetes or
Chagas disease were recruited while awaiting general medi-
cine and surgical clinics. All patients were screened for vol-
untary participation and were not matched by age or sex.
Patients were excluded if they were younger than 18, older
than 70, or had systemic or ophthalmologic disease known to
interfere with PLRs (including myasthenia gravis, multiple
sclerosis, amyloidosis, Parkinson’s disease, Alzheimer’s dis-
ease, pseudotumor cerebri, retinopathy, optic neuritis, binoc-
ular blindness, glaucoma, recent eye trauma, cataracts, prior
ocular surgery, binocular corneal scarring, bilateral pteryg-
ium, or anisocoria). Patients using ophthalmologic beta-blockers
were excluded from analysis, but Chagas patients and patients
with diabetes taking oral beta-blockers were included (N = 3).
Healthy controls taking any oral medications were excluded.
No Chagas patients recruited had concurrent heart failure.
Patients with both Chagas disease and diabetes were excluded
from primary analysis and later evaluated in secondary analy-
sis comparing dually diagnosed patients to those with either
Chagas disease or diabetes alone. Tobacco and coca leaf
are commonly used stimulants in Bolivia. Patients were not
excluded for historical use of either, but refrained from use
on the day of autonomic testing.
Clinical evaluation. Medical history and physical examina-
tions were obtained along with electrocardiogram (ECG) and
chest X-ray for all patients. This allowed for Kuschnir class
determination, which measures heart failure status in Chagas
disease. All included patients were either Kuschnir class
0 (no symptoms, normal ECG, and normal chest X-ray) or
Kuschnir class 1 (no symptoms, normal chest X-ray, but
abnormal ECG). Laboratory testing included 8-hour fasting
serum glucose, hemoglobin A1c, and serologic testing for
Trypanosoma cruzi. As recruitment occurred in 2008, diabe-
tes was defined as fasting serum glucose ≥ 126 mg/dL on two
separate occasions, random serum glucose ≥ 200 mg/dL with
symptoms, or hemoglobin A1c ≥ 7% (53 mmol/mol), rather
than the more recent definition of ≥ 6.5% (48 mmol/mol).16
Diabetic patients were predominantly type 2 and insulin use
was rare (N = 2). Chagas disease was confirmed by positive
results on both T. cruzi lysate enzyme-linked immunosorbent
assay (ELISA) (Weiner Laboratory, Rosario, Argentina) and
indirect hemagglutination assay (Lemos Laboratory, Buenos
Aires, Argentina). When tests were discordant, a recombinant
T. cruzi ELISA (Weiner Laboratory) served as tiebreaker.
Control patients were those who tested negative for both
Chagas disease and diabetes.
Conventional autonomic testing. Participants were sched-
uled for autonomic testing from 8 AM to 12 PM after an
8-hour fast, 8-hour sleep, and abstention from caffeine,
coca leaf, and tobacco. Patients confirmed these criteria
before testing. Respiratory variation of heart rate was per-
formed during six deep breaths lasting 10 seconds each while
lying supine. Continuous ECG rhythm strips (lead II) were
analyzed for the longest and shortest RR intervals during each
breath. Mean inspiratory and expiratory heart rates (longest
and shortest intervals, respectively) were calculated, with each
patient’s ratio defined as the inspiratory-to-expiratory ratio
(I : E ratio). After resting for 5 minutes, participants per-
formed a 15-second sustained Valsalva maneuver. The ratio
of the longest RR interval immediately following Valsalva
and the shortest RR interval during the subsequent minute
was defined as the Valsalva ratio, which was abnormal if
≤ 1.20, reflecting blunted variation.17,18 After resting 5 minutes
supine, patients rose to standing as fast as possible (ortho-
static testing). The ratio between the 30th RR interval and
the 15th RR interval immediately after standing was defined
as the orthostatic ratio (elsewhere called the 30:15 ratio),
which is abnormal if < 1.0.19 Because these ratios measure
the relationship between sympathetic and parasympathetic tone,
abnormalities in either system can blunt CAT measurements.
Pupillary light reflexes. PLRs were evaluated with custom-
built pupillometers based on laptop-based video eye move-
ment systems.20,21 Participants wore form-fitting motorcycle
goggles, which occlude the left eye and house a digital video
camera that images the right eye at 200 frames/second (Firefly
MV, Point Grey Research, Inc., Richmond, BC, Canada).
The right eye was illuminated by two infra-red light-emitting
diodes (LEDs) (HSDL 4200, Agilent Technologies, Inc.,
Santa Clara, CA) at a wavelength of 875 nm, which is invis-
ible to the subject. An infrared pass filter (FIL-IR730/10,
Allthings.com.au) at the back of the camera lens prevents
imaging of visible wavelengths from the LEDs. A wideband
“hot” mirror reflects the image onto the camera lateral to the
subject’s field of view. A 40 × 40 mm cell phone backlight dis-
play (LCD-08842, SparkFun Electronics) is supported 30 mm
from the eye and contains six white LEDs with programmable
flash duration and brightness and a diffuser to provide even
illumination. The goggles occlude all ambient light and weigh
60 g. The goggle-mounted camera was connected via firewire
to a laptop running Windows XP (Microsoft Corp., Seattle,
WA) and LabVIEW (National Instruments, Austin, TX).
After CAT, patients rested for 5 minutes before putting on
PLR goggles, which were calibrated using a monochrome
image to clearly delineate the pupil from the sclera. Patients
then experienced 120 seconds in total darkness to establish
FIGURE 1. Pupillary light reflex parameters, associated autonomic
control, and study findings.
1291PUPILLARY LIGHT REFLEXES IN CHAGAS DISEASE AND DIABETES
baseline pupil size. Next, they experienced 20 light pulses at
an intensity of 30 cd/m2, lasting 100 ms each and separated
by random intervals of 4.5–5.5 seconds of darkness. Pupil size
was determined by both center-of-mass and ellipse-fit methods
at a rate of 200 Hz.20–22 Both measures yield identical results,
so center-of-mass calculations were used when pupil images
were not obstructed by eyelids or lashes, and ellipse-fit calcula-
tions were used for obstructed images.
PLR parameters calculated included: 1) baseline pupil
radius—initial pupil radius before the light stimuli; 2) mini-
mum pupil radius—minimum pupil radius after the light stimu-
lus before redilation; 3) latency to onset of constriction—time
between onset of light stimulus and initiation of pupillary con-
striction; 4) maximum constriction velocity—maximum rate of
change in pupil size during constriction following light stimu-
lus; 5) amplitude of pupillary reaction—difference between
initial pupil diameter and minimum pupil diameter after light
stimulus; 6) latency of maximum constriction—time from onset
of light stimulus to minimum pupil diameter, 7) redilation
latency—time between cessation of light stimulus and initia-
tion of pupil redilation, which can be negative if the pupil
dilates before cessation of light stimulus; 8) maximum
redilation velocity—maximum rate of change in pupil size dur-
ing redilation; and 9) time to 75% redilation—time required
after cessation of light stimulus for the pupil to redilate to
75% of the initial pupil diameter. Mean values of each param-
eter were calculated for each participant. Constriction ratio
was calculated as minimum pupil radius divided by baseline
pupil radius.23
Statistical analysis. Data were entered using Microsoft
Access 2007 (Microsoft Corp.), then cleaned and analyzed
using STATA Version 11.0 (StataCorp LP, College Station,
TX). Demographic and PLR differences were compared using
two-tailed t tests or analysis of variance, as appropriate.
Adjusted mean PLR parameters were calculated from multi-
variate linear regressions including sex, age, and use of any
of the following medications (defined as a single variable):
statins, spironolactone, diuretics, amiodarone, warfarin, cal-
cium channel blockers, aspirin, angiotensin-converting enzyme
inhibitors, beta-blockers, or proton-pump inhibitors. Multi-
variate linear regressions were constructed comparing mean
PLR values between diabetic patients, Chagas disease patients,
and controls according to CAT results. Chagas disease patients
and controls were pooled as “nondiabetes” to differentiate
PLR variables between patients with and without diabetes.
The heteroskedasticity-consistent estimator of standard errors
was used to reduce standard deviation variability from rela-
tively small sample size.24 Patients with both diabetes and
Chagas disease were not included in primary analysis, but
compared with diabetic patients without Chagas disease in
secondary analysis.
Multivariate logistic regression models were constructed
to correlate adjusted PLR parameters with abnormal CAT
results. To identify parameters that best correlated with
laboratory-confirmed diabetes, thereby indicating “diabe-
tes complicated by autonomic dysfunction,” PLR variables
were dichotomized using cut points maximizing area under
the receiver operating characteristic curve (AUC). Multivari-
ate logistic regressions were constructed with demographic,
clinical, and dichotomized PLR variables against diabetes sta-
tus. PLR parameters with P < 0.30 in bivariate analysis were
included in multivariate logistic regressions models with back-
ward stepwise construction using P < 0.25 as a cutoff. Clini-
cal variables affecting autonomic test parameters such as age
and sex were also included. A clinical prediction score—the
average pupillary pulsed light evaluation (APPLE) response
score—was constructed to identify patients with “diabetes
complicated by autonomic dysfunction,” defined as “abnormal
PLRs in a diabetic patient.” The score assigned points equal
to the lowest common denominator of logistic regression coef-
ficients, rounded to increments of the nearest 0.5.25 Discrimi-
nation ability and calibration were evaluated by AUC and
the Hosmer–Lemeshow statistic, respectively. The APPLE
response score was internally validated using bootstrap aggre-
gation of AUC across 200 replications, and an optimism-
corrected AUC was calculated to assess for overfitting.26
RESULTS
Patient characteristics. Initial recruitment included 192
patients, 29 of whom were excluded due to ophthalmologic
problems, leaving 163 patients for analysis: 96 patients with
Chagas disease, 35 with diabetes, and 32 controls (Table 1).
Overweight and obesity were common among the study
population (32.7% and 38.7%, respectively), though body
mass index was not significantly different between controls,
patients with diabetes, and Chagas disease patients. Smoking
was uncommon (9.2% of patients) and did not differ signifi-
cantly between groups. Patients with diabetes were more
likely to be older, hypertensive, take medications, and have
a higher waist-to-hip ratio than those with Chagas disease or
controls. They were also more likely to be male, obese, and
smokers, though these results were not statistically signifi-
cant. Total pack-years smoked was not different between
groups. Though both patients with diabetes and Chagas
disease patients were more likely to take medications than
controls, only statin use was statistically significantly different
between patients with diabetes and nonpatients with diabetes.
Only three of 163 patients used beta-blockers, which was not
different between groups. Among patients with diabetes, two
(5%) took only insulin, 27 (64%) took only oral hypoglyce-
mic medicines, and six (14%) used both.
Autonomic testing results. Results of both PLRs and CAT
parameters are presented in Table 2 (unadjusted results) and
Table 3 (adjusted results). Compared with both patients with
Chagas disease and healthy controls, diabetic patients had
smaller baseline pupil radius, increased latency to constric-
tion, slower maximum constriction velocity, and decreased
amplitude of pupillary reaction, which together demonstrate
blunting of both sympathetic and parasympathetic pathways
(Table 2). Though not statistically significant, patients with
Chagas disease also tended to have smaller amplitude of
pupillary reaction and maximum redilatation velocity com-
pared with controls. The orthostatic ratio and the I : E ratio
were both statistically significantly different between patients
with diabetes and controls. Both ratios were largest in con-
trols, smallest in patients with diabetes, and intermediate
in Chagas disease, suggesting more autonomic dysfunction
among patients with diabetes than Chagas disease patients
by both tests (Table 2). The rate of abnormal orthostatic or
Valsalva results was not statistically significant between groups
for either ratio. After adjusting for age, sex, and medica-
tions taken, patients with diabetes had longer mean latency
to onset of constriction and slower maximum constriction
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TABLE 2
Mean pupillary light reflex (PLR) and conventional autonomic test (CAT) parameters, by Chagas disease and diabetes status
(A) Control patients (B) Chagas disease patients (C) Diabetic patients P value*
N Mean 95% CI N Mean 95% CI N Mean 95% CI A vs. B A vs. C B vs. C
PLR parameters†
Baseline pupil radius 30 23.79 22.72, 24.87 94 23.00 22.22, 23.78 34 21.10 19.78, 22.42 0.30 < 0.01 0.01
Latency to onset of
constriction
30 0.21 0.19, 0.22 94 0.22 0.21, 0.22 34 0.26 0.23, 0.29 0.21 < 0.01 < 0.01
Maximum constriction
velocity
29 −3645.1 −4086.2,
−3204.0
91 −3318.9 −3490.2,
−3147.5
33 −2771.1 −3034.2,
−2508.0
0.10 < 0.01 < 0.01
Amplitude of pupillary
reaction
30 7.61 6.98, 8.25 94 6.93 6.57, 7.29 34 6.57 5.97, 7.17 0.09 < 0.01 0.33
Latency of maximum
constriction
30 0.77 0.76, 0.79 94 0.78 0.76, 0.80 34 0.77 0.74, 0.80 0.70 0.93 0.76
Redilation latency 30 0.68 0.66, 0.69 94 0.69 0.67, 0.71 34 0.68 0.65, 0.71 0.63 0.69 0.92
Maximum redilation
velocity
30 1394.9 724.5, 2065.3 94 1244.0 865.3, 1622.7 34 1065.40 435.7, 1695.2 0.02 0.21 0.74
Time to 75%
redilation
30 1.00 0.93, 1.08 94 0.98 0.94, 1.02 34 0.96 0.89, 1.03 0.59 0.22 0.60
Constriction ratio 30 0.54 0.50, 0.57 94 0.52 0.50, 0.54 34 0.51 0.48, 0.54 0.50 0.14 0.59
Reaction ratio 30 0.68 0.67, 0.69 94 0.69 0.67, 0.71 34 0.68 0.65, 0.71 0.60 0.95 0.64
CAT parameters
Orthostatic ratio 31 1.26 1.21, 1.31 87 1.21 1.18, 1.24 34 1.14 1.09, 1.19 0.11 < 0.01 0.02
≤ 1.0 0 0.0‡ – 2 2.3‡ 0.3, 8.1 3 8.8‡ 1.9, 23.7 1.00§ 0.24§ 0.13§
> 1.0 31 100.0‡ – 85 97.7‡ 91.9, 99.7 31 91.2‡ 76.3, 98.1
I : E ratio 31 1.22 1.18, 1.27 91 1.18 1.15, 1.20 34 1.16 1.12, 1.20 0.07 0.05 0.44
Valsalva ratio 30 1.41 1.32, 1.49 87 1.33 1.28, 1.39 34 1.31 1.23, 1.39 0.15 0.10 0.66
≤ 1.2 8 26.7‡ 12.3, 45.9 24 27.6‡ 18.5, 38.2 13 38.2‡ 22.2, 56.4 1.00§ 0.43§ 0.28§
< 1.2 22 73.3‡ 54.1, 87.7 63 72.4‡ 61.8, 81.5 21 61.8‡ 43.6, 77.8
95% CI = 95% confidence interval.
*P value calculated by T-tests between each pair of disease profile groups (A, B, C), except as specified by the symbol “§” indicating use of a Fischer’s exact test.
†Units for pupillometric variables were pixels for static distances, seconds for time, and pixels per second for velocity metrics.
‡Instead of a mean value, this number represents the percentage of patients with disease profile with CAT value as described.
TABLE 1
Patient demographics and clinical characteristics
Variable
Controls (N = 32) Diabetic patients (N = 35) Chagas patients (N = 96)
P value*n % n % n %
Female sex 19 59.4 23 34.3 69 71.9 0.40
Age (years)† 31 39.8 (12.7) 35 50.7 (10.0) 96 46.7 (10.5) < 0.01
Body mass index (kg/m2)‡ 31 27.5 (7.3) 34 29.7 (6.5) 91 27.3 (6.7) 0.41
Normal weight (18.5–24.9 kg/m2) 8 25.8 6 17.7 26 28.6 0.66
Overweight (25.0–29.9 kg/m2) 10 32.3 11 32.3 32 35.2
Obese (> 30.0 kg/m2) 13 41.9 17 50.0 33 36.3
Waist: hip ratio‡ 31 0.89 (0.09) 34 0.91 (0.06) 90 0.90 (0.09) 0.14
High waist: hip ratio§ 20 64.5 31 91.2 58 64.4 0.01
Current smoking 3 9.4 6 17.1 6 6.3 0.16
Smoking history (pack-years)‡ 32 0 (0.3) 34 0 (2.5) 91 0 (0) 0.25
Hypertension 1 4.0 11 34.4 21 23.9 0.02
Coronary heart disease 1 3.6 3 8.6 4 4.4 0.60
Kuschnir class 1 NA NA 59 61.5 NA
Took any regular medications¶ 0 0.0 29 82.9 32 33.3 < 0.01
Calcium channel blockers 0 0.0 0 0.0 3 3.1 0.57
Beta-blockers 0 0.0 1 2.86 2 2.08 1.00
ACE inhibitors 0 0.0 6 17.1 16 16.7 0.02
Spironolactone 0 0.0 2 5.7 3 3.1 0.48
Diuretics 0 0.0 2 5.7 5 5.2 0.57
Aspirin 0 0.0 3 8.6 7 7.3 0.29
Anticoagulants 0 0.0 0 0.0 2 2.1 1.00
Statins 0 0.0 5 14.3 1 1.0 < 0.01
Thyroid supplements 0 0.0 1 2.9 1 1.0 0.66
Digoxin 0 0.0 0 0.0 2 2.1 1.00
Amiodarone 0 0.0 0 0.0 5 5.2 0.22
Contraceptives 0 0.0 1 2.9 4 4.2 0.82
ACE = angiotensin-converting enzyme; ANOVA = analysis of variance; NA = not applicable.
*P value represents ANOVA between all three groups (those with diabetes, those with Chagas disease, and those with neither).
†% Column represents mean (standard deviation).
‡% Column represents median (interquartile range).
§High waist-to-hip ratio was defined as ≥ 0.90 for males and ≥ 0.85 for females.
¶Included any of the following medications: calcium channel blockers, beta-blockers, ACE inhibitors, spironolactone, diuretics, aspirin, anticoagulants, statins, thyroid supplements, digoxin,
amiodarone, or contraceptives.
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velocities than Chagas and control patients with a trend
toward smaller baseline pupil radius and smaller orthostatic
ratios (Table 3). No significant difference was found between
PLR values among patients with Chagas disease and controls.
After adjustment for age, sex, and medication use, diabetic
patients had longer latency to onset of pupillary constriction,
slower maximum constriction velocity, smaller orthostatic ratio,
and nonsignificant trends toward smaller baseline pupil radius
TABLE 3
Adjusted mean pupillary light reflex (PLR) and conventional autonomic test (CAT) parameters,* by Chagas disease and diabetes status
(A) Control patients (B) Chagas disease patients (C) Diabetic patients P value†
N Mean 95% CI N Mean 95% CI N Mean 95% CI A vs. B A vs. C B vs. C
PLR parameters‡
Baseline pupil radius 30 29.16 26.65, 31.68 94 29.40 26.88, 31.92 34 28.04 25.14, 30.94 0.75 0.22 0.06
Latency to onset of
constriction
30 0.16 0.13, 0.2 94 0.17 0.14, 0.21 34 0.21 0.17, 0.25 0.50 0.02 0.01
Maximum
constriction
velocity
29 −5253.8 −6150.8, −4356.7 91 −5134.0 −5837.2, −4430.9 33 −4741.90 −5520.4, −3963.3 0.51 0.02 0.03
Amplitude of
pupillary reaction
30 8.66 7.32, 10 94 8.12 6.78, 9.47 34 7.95 6.4, 9.49 0.18 0.14 0.65
Latency of maximum
constriction
30 0.74 0.69, 0.78 94 0.75 0.69, 0.81 34 0.74 0.67, 0.8 0.63 0.97 0.66
Redilation latency 30 0.64 0.59, 0.69 94 0.65 0.59, 0.7 34 0.64 0.58, 0.71 0.61 0.83 0.79
Maximum redilation
velocity
30 1131.6 −35.6, 2298.8 94 1021.6 245.0, 1798.1 34 814.96 −443.2, 2073.2 0.09 0.24 0.77
Time to 75%
redilation
30 0.87 0.72, 1.02 94 0.83 0.68, 0.98 34 0.80 0.63, 0.98 0.41 0.24 0.52
Constriction ratio 30 0.50 0.43, 0.57 94 0.48 0.41, 0.55 34 0.47 0.39, 0.55 0.39 0.26 0.60
Reaction ratio 30 0.70 0.64, 0.76 94 0.72 0.66, 0.78 34 0.71 0.64, 0.78 0.31 0.71 0.56
CAT parameters
Orthostatic ratio 31 1.39 1.28, 1.51 87 1.37 1.26, 1.49 34 1.32 1.19, 1.45 0.48 0.05 0.07
≤ 1.0 0 0.0§ – 2 1.5§ 0, 65.6 3 4.8§ 0, 89.7 – – 0.27
> 1.0 31 100.0§ – 85 98.5§ 34.4, 99.9 31 95.2§ 10.3, 99.9
I : E ratio 31 1.39 1.28, 1.51 91 1.37 1.26, 1.48 34 1.37 1.25, 1.49 0.37 0.43 0.92
Valsalva ratio 30 1.57 1.39, 1.74 87 1.54 1.34, 1.73 34 1.52 1.32, 1.72 0.58 0.48 0.76
≤ 1.2 8 27.6§ 6.5, 67.8 24 21.0§ 4.4, 60.3 13 31.4§ 6, 76.6 0.48 0.76 0.25
< 1.2 22 72.4§ 32.2, 93.5 63 79.0§ 39.7, 95.6 21 68.6§ 23.4, 94
95% CI = 95% confidence interval.
*Adjusted for age, sex, and use of any of the following medications: calcium channel blockers, beta-blockers, angiotensin-converting enzyme inhibitors, spironolactone, diuretics, aspirin, anti-
coagulants, statins, thyroid supplements, digoxin, amiodarone, or contraceptives.
†P values calculated by T-tests between each pair of disease profile groups (A, B, C).
‡Units for pupillometric variables were pixels for static distances, seconds for time, and pixels per second for velocity metrics.
§Instead of a mean value, this number represents the percentage of patients with disease profile with CAT value as described.
TABLE 4
Adjusted means of pupillary light reflex and conventional autonomic testing parameters, by diabetes status*
Patients without diabetes Patients with diabetes
P valueN Mean 95% CI N Mean 95% CI
Pupillometric parameters†
Baseline pupil radius 124 29.28 26.88, 31.68 34 27.97 25.11, 30.83 0.06
Latency to onset of constriction 124 0.17 0.13, 0.21 34 0.21 0.16, 0.26 < 0.01
Maximum constriction velocity 120 −5191.28 −5788.25, −4594.32 33 −4772.83 −5478.33, −4067.33 0.02
Amplitude of pupillary reaction 124 8.55 7.60, 9.50 34 8.04 6.91, 9.18 0.07
Latency of maximum constriction 124 0.74 0.67, 0.81 34 0.73 0.65, 0.82 0.72
Redilation latency 124 0.64 0.58, 0.71 34 0.64 0.57, 0.72 0.87
Maximum redilation velocity 124 1393.94 809.79, 2455.67 34 1377.69 681.77, 2073.62 0.92
Time to 75% redilation 124 0.85 0.71, 0.99 34 0.82 0.65, 0.99 0.39
Constriction ratio 124 0.49 0.42, 0.55 34 0.48 0.39, 0.55 0.46
Reaction ratios 124 0.71 0.65, 0.77 34 0.71 0.64, 0.78 0.72
Autonomic parameters
Orthostatic ratio 118 1.39 1.29, 1.48 34 1.33 1.21, 1.44 0.05
≤ 1.0‡ 2 0.8 0.0, 45.6 3 3.5 0.0, 85.2 0.16
> 1.0‡ 116 99.2 54.4, 100.0 31 96.5 24.8, 100.0
Valsalva ratio 117 1.55 1.38, 1.73 34 1.53 1.32, 1.74 0.65
≤ 1.2‡ 32 24.4 5.8, 62.8 13 33.8 6.8, 78.1 0.32
> 1.2‡ 85 75.6 37.2, 94.2 21 66.2 21.9, 93.2
I : E ratio 122 1.38 1.30, 1.47 34 1.38 1.28, 1.48 0.76
95% CI = 95% confidence interval.
*Adjusted for sex, age, and use of the following medications: statins, spironolactone, diuretics, amiodarone, warfarin, calcium channel blockers, aspirin, angiotensin-converting enzyme inhibi-
tors, beta-blockers, and proton-pump inhibitors.
†Units for pupillometric variables were pixels for static distances, seconds for time, and pixels per second for velocity metrics.
‡Percentage (95% confidence interval), otherwise mean (95% CI).
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and smaller amplitude of pupillary reaction than nonpatients
with diabetes, indicating both sympathetic and parasympa-
thetic dysfunction among patients with diabetes (Table 4).
Evaluation of patients diagnosed with both Chagas disease
and diabetes (N = 43) revealed a slightly shorter latency to
onset of constriction after adjustment for age, sex, and medi-
cation use than among diabetic patients without Chagas
disease (0.18 versus 0.21 seconds, P = 0.046) and a trend
toward smaller Valsalva ratios among those with both diag-
noses. Among diabetic patients, Chagas disease status did
not significantly affect I : E ratio (P = 0.448), Valsalva ratio
(P = 0.216), or orthostatic ratio (P = 0.94). No other statisti-
cally significant difference or trend was found that differenti-
ated patients with diabetes with and without Chagas disease
or that differentiated Chagas disease patients with or without
diabetes (data not shown).
Correlation between PLRs and conventional autonomic
tests. Multivariate logistic regressions compared each PLR
parameter and the presence of diabetes or Chagas disease to
abnormal CAT results. No significant differences were found
for any PLR parameter between patients with diabetes with
normal CAT results and patients with diabetes with abnormal
CAT results. Patients with diabetes with abnormal Valsalva
ratios trended toward decreased baseline pupil radius (25.95
versus 28.73 pixels, P = 0.06) and slower maximum constric-
tion velocity (−4261.1 versus −4957.8 pixels/second, P = 0.09)
compared with patients with diabetes with normal Valsalva
ratios, suggesting both sympathetic and parasympathetic
dysfunction. Similarly, no significant differences were found
for any PLR parameter between nondiabetic patients with
abnormal CAT results and nondiabetic patients with normal
CAT results.
After adjustment for age, sex, and use of medications, PLR
parameters were compared with each individual CAT variable
as well as with a composite variable of “any abnormal CAT
result.” Among patients with diabetes, those with “any abnor-
mal CAT results” were noted to have longer latency to onset
of constriction, slower maximum constriction velocity, as well
as nonsignificant trends toward smaller baseline pupil radius,
smaller amplitude of pupillary reaction, and faster maximum
redilatation velocity, suggesting mixed sympathetic and para-
sympathetic dysfunction in these patients (Table 5). No PLR
parameters were even modestly correlated with abnormal
CAT among nonpatients with diabetes (data not shown).
TABLE 5
Adjusted means of pupillary light reflex parameters* by conventional autonomic test results in diabetic patients†
Variable
Normal I : E/orthostatic/Valsalva ratio Abnormal I : E/orthostatic/Valsalva ratio
P valueN Mean 95% CI N Mean 95% CI
Baseline pupil radius 20 28.44 21.88, 35.01 13 26.00 19.24, 32.77 0.06
Latency to onset of constriction 20 0.22 0.05, 0.39 13 0.28 0.11, 0.46 0.04
Maximum constriction velocity 20 −3850.6 −5371.6, −2329.5 12 −3183.2 −4769.1, −1606.24 0.04
Amplitude of pupillary reaction 20 6.26 3.95, 8.56 13 5.58 3.21, 7.95 0.14
Latency of maximum constriction 20 0.67 0.56, 0.78 13 0.66 0.55, 0.78 0.78
Redilation latency 20 0.58 0.46, 0.69 13 0.60 0.46, 0.68 0.75
Maximum redilation velocity 20 1446.9 −725.3, 3619.1 13 2002.9 −232.9, 4238.8 0.19
Time to 75% redilation 20 0.43 0.21, 0.65 13 0.41 0.18, 0.63 0.66
Constriction ratio 20 0.37 0.26, 0.47 13 0.37 0.26, 0.47 0.91
Reaction ratio 20 0.81 0.73, 0.88 13 0.80 0.72, 0.88 0.95
95% CI = 95% confidence interval.
*Units for pupillometric variables were pixels for static distances, seconds for time, and pixels per second for velocity metrics.
†Adjusted for age, sex, and use of selected medications (statins, spironolactone, diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, and proton-pump inhibitors).
TABLE 6
Average pupillary pulsed light evaluation response score using pupillary light reflexes to identify diabetes complicated by pupillary autonomic
dysfunction*
Variable β-coefficient (95% CI) Adjusted† OR (95% CI) Points
Baseline pupillary radius
≤ 22.80 0.00 1.00 0
> 22.80 0.98 (−0.13, 2.09) 4.24 (1.67, 10.75) 2
Latency to onset of constriction
≤ 0.22 0.00 1.00 0
> 0.22 1.44 (0.51, 2.38) 3.79 (1.55, 9.29) 3
Maximum constriction velocity
≤ −3260.39 0.00 1.00 0
> −3260.39 0.69 (−0.45, 1.83) 1.99 (0.64, 6.25) 1.5
Sex
Male 0.00 1.00 0
Female 0.17 (−0.76, 1.09) 1.18 (0.47, 2.98) 0.5
Age
≤ 47 years 0.00 1.00 0
> 47 years 0.52 (−0.38, 1.42) 1.69 (0.69, 4.14) 1
AUC
Uncorrected AUC‡ 0.77 (0.70, 0.85)
Optimism-corrected AUC‡ 0.71 (0.62, 0.79)
AUC = area under the ROC curve; 95% CI = 95% confidence interval; OR = odds ratio; ROC = receiver operating curve.
*Units for pupillometric variables were pixels for static distances, seconds for time, and pixels per second for velocity metrics.
†Adjusted for the other parameters included in the logistic regression model (parameters shown).
‡Area under the ROC curve (95% CI).
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Development of APPLE response clinical score to differ-
entiate patients with and without diabetes. Table 6 presents
the PLR parameters that found to be significantly associated
with diabetes as the APPLE response score. This score was
defined as the finding of abnormal PLR in diabetic patient,
indicating “diabetes complicated by autonomic dysfunction”
that was not necessarily observed on CAT. AUC for this
model was 0.77 (95% confidence interval [CI] 0.70, 0.85),
which fell to 0.71 (95% CI 0.62, 0.79) after optimism correc-
tion. The final model was not improved by including CAT
variables. Selected cutoff values are presented in Table 7
with their respective sensitivity, specificity, and positive and
negative likelihood ratios for the identification of patients
with “diabetes complicated by pupillary autonomic dysfunc-
tion.” Those patients with APPLE response scores ≥ 5.5 are
2.27 times as likely as those with lower scores to have “dia-
betes complicated by pupillary autonomic dysfunction” (sen-
sitivity: 87.9%, specificity: 61.3%). Increased likelihood of
“diabetes complicated by pupillary autonomic dysfunction”
was found with larger APPLE response scores at the cost of
sensitivity and negative predictive value.
DISCUSSION
This study represents the first comparison of PLRs and
CAT in patients with Chagas disease and the first attempt to
define PLR cut points to identify diabetic autonomic dys-
function. Though patients with Chagas disease can develop
autonomic dysfunction, PLRs could not differentiate patients
with Chagas disease from controls, nor could they differenti-
ate Chagas disease patients with normal CAT results from
those with abnormal CAT results in this study.8
Trypanosoma cruzi localizes to the heart and intestines
and contributes to parasympathetic dysfunction at those sites
over time.27,28 Over the last few decades, several mechanisms
have been proposed through which Chagasic cardiac and
gastrointestinal dysfunction may occur. These include direct
damage to the tissue by live parasites, so-called “bystander”
damage caused to the tissue through host defenses targeting
the parasite, and autoimmune destruction of these tissues
by a combination of cellular and humoral immune responses
to cardiac proteins released when the parasite damages car-
diac myocytes. The relative significance of these mecha-
nisms has been debated for years. At a minimum, there is
a poor correlation between the degree of cardiac dysfunc-
tion and parasite burden found on histopathologic evalua-
tion that suggests more to the story than simple parasite
persistence.29,30 On the other hand, antibodies have been
identified in Chagas disease that target beta-adrenergic recep-
tors, but despite a biologically plausible association with
autonomic dysfunction, these have not been shown to be asso-
ciated with either the extent of cardiac disease nor unique to
Chagasic cardiomyopathy.30,31 One major aspect of this debate
is its implication for treatment decisions, since an autoim-
mune pathophysiology would minimize the role for specific
antiparasitic therapy. This discussion has recently grown more
significance in light of the BENEFIT trial published last year,
which confirmed that benznidazole treatment reduced parasite
detection by polymerase chain reaction, but found no differ-
ence in cardiac events after treatment of cardiac Chagas dis-
ease patients with mild heart disease.32 As the topic continues
to be debated, it is reasonable to consider that some combina-
tion of the multiple proposed mechanisms is at play, but for the
time being, the data presented here suggest that the autonomic
pathways controlling PLRs are not affected in Chagas disease,
and PLRs are not a useful tool for the evaluation of Chagas
disease patients.
In contrast, diabetic patients were found to have multiple
differences in their PLRs compared with both Chagas dis-
ease patients and controls. Unlike Chagas disease, diabetes
causes global autonomic impairment.1 Patients with diabe-
tes in this study were found to have autonomic dysfunction
measured by both CAT and PLRs (Table 4). The decreased
baseline pupil radius among diabetic patients reflects altered
sympathetic tone, which was not found among those with
Chagas disease, consistent with the pathophysiology of each
condition. On the other hand, latency to onset, maximum
constriction velocity, and amplitude of pupillary reaction
reflect more parasympathetic tone, which would be expected
in Chagas disease if it affected the pupils, though no signifi-
cant association was found.11–13 Diabetic patients with CAT
abnormalities demonstrated PLR abnormalities that were
more advanced than diabetic patients without CAT abnor-
malities, but when diabetic patients develop CAT abnormali-
ties, it is too late to reverse autonomic dysfunction even with
tight glycemic control.10
No single test of cardiac autonomic function has been shown
to have sufficient sensitivity and specificity to be used alone
to evaluate dysfunction among diabetic patients.6,9 Although
CAT has demonstrated differences between patients with and
without Chagas disease, PLRs did not reliably differentiate
patients with and without autonomic dysfunction by CAT.8,12
This was true for both Chagas disease and for diabetes and
likely reflects the larger extent of autonomic dysfunction
required to develop truly abnormal CAT values. Patients
with Chagas disease, for example, are known to have lower
Valsalva ratios than healthy controls, but a recent meta-
analysis found the average Valsalva ratio among Chagas
patients to be 1.74, which is well within the limits of nor-
mal.3,33 Likewise, previous studies have demonstrated dif-
ferences between PLR parameters of healthy and diabetic
subjects, and PLR abnormalities can be found among patients
with diabetes with and without abnormalities on CAT.14,15,34–36
Abnormal PLRs have been associated with future microvascu-
lar disease and may be associated with future CAT abnormali-
ties.15,37 By the time CAT abnormalities develop in diabetes,
even tight glycemic control will not reduce mortality,10 sug-
gesting that abnormal CAT findings may be a threshold effect
rather than a point along the reversible spectrum of morbid-
ity. If dysfunction is tolerated in multiple organs up to the
TABLE 7
APPLE response score as a clinical predictor of diabetes, sensitivity,
specificity, and likelihood ratios (LRs)
Cutoff points Sensitivity (%) Specificity (%) Correctly classified (%) LR+ LR−
≥ 5.0 93.9 54.6 63.2 2.07 0.11
≥ 5.5 87.9 61.3 67.1 2.27 0.20
≥ 6.0 81.8 63.9 67.8 2.26 0.28
≥ 6.5 78.8 66.4 69.1 2.34 0.32
≥ 7.0 72.7 68.1 69.1 2.28 0.40
≥ 7.5 51.5 79.0 73.0 2.45 0.61
≥ 8.0 45.5 81.5 73.7 2.46 0.67
APPLE = average pupillary pulsed light evaluation; LR+ = positive likelihood ratio,
LR− = negative likelihood ratio.
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point that irreversible damage occurs and the risk of adverse
events increases, surrogate measures like abnormal PLRs
might identify patients in need of intense glycemic control
before irreversible damage sets in. In the interest of finding an
endpoint upstream from irreversible cardiac autonomic dys-
function, this study attempted to develop a diagnostic model for
asymptomatic autonomic dysfunction in patients with diabetes.
The model presented in this article (the APPLE response
score) uses a combination of three pupillometric parameters:
baseline pupil radius, latency to onset of constriction, and
maximum constriction velocity, along with age and sex for
evaluating patients with diabetes. Although the score was
derived from evaluation of patients with laboratory-confirmed
diabetes, the construction of this model means that the risk
score measures not likelihood of “having diabetes” but of
“having diabetes complicated by autonomic neuropathy.” This
score will need to be validated in prospective cohorts to deter-
mine its utility in predicting cardiac autonomic dysfunction
and macrovascular complications. Once validated, PLRs and
the APPLE response score may be preferred over CAT for
the evaluation of autonomic dysfunction due to shorter test
duration (< 2 minutes versus ∼20 minutes in this protocol),
minimal training required of clinic staff, and its association
with microvascular complications such as retinopathy and
nephropathy that can be prevented by tight glycemic control.
This cross-sectional study had several important limita-
tions. Patients with diabetes tend to be diagnosed after sev-
eral years without symptoms, so many patients with currently
well-controlled disease have unknown amounts of previous
damage. This cross-sectional study could not, therefore, deter-
mine how long patients had been affected by either Chagas
disease or diabetes, and it could not evaluate adequacy of
prior diabetes control. Since autonomic function measure-
ments by both CAT and PLRs are indicators of cumulative
damage, this study cannot speculate on the extent to which
time with disease affects PLR or CAT variables.38 Likewise,
the exclusion of patients with significant eye disease likely
excluded advanced diabetic patients with poor autonomic
function. The exclusion of people using medications such
as eye drops that directly affect PLRs may also limit general-
izability of these data to patients taking those medications.
Many patients with either diabetes or heart failure take med-
ications such as beta-blockers that directly affect autonomic
activity. No patients in this study had heart failure and only
three took beta-blockers. Medication effects were not found
to significantly alter PLRs in this study, but practitioners
should be cautious in generalizing these results until they
are confirmed in a population with higher rates of medica-
tion use, such as in the United States. Though different PLR
results were apparent between patients with and without
diabetes, the fact that no statistically significant differences
were found on CAT between Chagas disease patients and
controls may reflect a small control group, which would
mask differences between patients with and without Chagas
disease. Additionally, the pupillometer in this study was
developed by the authors and is not available outside of
clinical protocols.21 Multiple devices are available commer-
cially at costs from $3,000 to $30,000. As more data are
generated about PLRs, standardized devices may become more
available, thereby increasing their clinical application. Finally,
this cross-sectional study could not provide any test of the
prognostic role of PLRs or the APPLE response score for
future cardiac complications, both of which remain areas for
future research.
Despite these limitations, evaluation of PLRs using the
risk score presented here represents a promising screening
tool for the evaluation of subclinical diabetic autonomic
dysfunction that appears to be more sensitive than CAT.
This testing can be easily performed in the clinic or at pub-
lic health fairs with little time, a computer, and minimally
trained staff. Though diabetes itself is easily diagnosed using
hemoglobin A1c and fasting glycemia, the risk score devel-
oped in this study may help identify diabetic patients with
subclinical autonomic dysfunction who need more aggressive
therapy earlier than evaluation with CAT. In particular, this
approach could have implications for developing world and
rural health care settings such as Bolivia with high rates of
diabetes (6.29%) and limited resources to perform wide-
spread laboratory-based screening programs.39 As a chronic
condition affecting so many people in lower and middle
income countries, autonomic dysfunction associated with
diabetes and Chagas disease merits further attention so that
testing and potential treatment options can become more
widely available. Pupillometry does not appear to have a role
in the evaluation of autonomic dysfunction in patients with
Chagas disease.
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